BSE Pharma Sector Regulatory Filings — May 11, 2026

Board meeting May 22, 2026, to approve FY26 audited results and recommend final dividend (highest materiality 8/10 vs peers)

Extended trading window closure until May 24, 2026 (from April 1), signals disciplined governance and major announcement prep

Board meeting May 18, 2026, for Q4/FY26 audited standalone/consolidated results (materiality 6/10), trading window closed from April 1 until 48hrs post-results

Sun group dual catalysts (May 18 + May 22) with dividend inclusion only at parent (8/10 vs 6/10 materiality) indicates outperformance

May 18 board meeting to approve Director's/Secretarial Audit Reports FY26 and fix AGM/book closure dates (CIN L24299GJ1992PLC018210)

Uniform compliance with SEBI Reg 29 and trading window closures from April 1, 2026, reflects strong governance amid no insider trades

Potential final dividend recommendation for FY25-26 shareholder approval at AGM, capital allocation focus post-results

May 18 cluster (2/3 filings), higher materiality SPARC (6/10 vs 3/10) positions Sun affiliate for relative strength

NSE SUNPHARMA/BSE 524715, large-cap leader scheduling results+dividend amid sector quiet period

3/3 BSE Pharma constituents with FY26 results catalysts in 7-11 days, no adverse insider activity

Scrutinizer appointment for e-voting/AGM signals proactive governance upgrades

Coordinated May 18-22 timeline, trading windows aligned from April 1, high conviction in FY26 delivery

Lowest materiality 3/10 board meeting, routine ratifications from 2024 EGM may signal lingering unresolved issues

Prolonged closure until May 24, 2026 (Sunday), delays insider conviction signals post-results

Trading window reopens only 48hrs after May 18 results declaration, limits near-term insider buying visibility

'Other business' subject to Chairman permission introduces potential unannounced items

Absence of any YoY/QoQ trends, ratios, or operational metrics pre-meetings heightens earnings miss risk

'If any' final dividend recommendation conditional, no YoY capital allocation trends disclosed

Zero reported transactions/pledges due to closures since April 1, masks management conviction

Small-cap (scrip 543207) with 3/10 materiality vs Sun Pharma 8/10, vulnerable to relative underperformance

No forward-looking guidance or M&A details across 3 filings, neutral sentiment amplifies results volatility

Research-focused arm tied to Sun Pharma, dependent on parent dividend/outlook for momentum

Position for FY25-26 final dividend recommendation at May 22 board, potential yield boost vs peers

May 18 FY26 results from research leader (scrip 532872), trade pre-results runup with window reopening soon after

Dual May 18-22 meetings (Sun + SPARC), arbitrage relative performance (8/10 vs 6/10 materiality)

May 18 fixes book closure/AGM dates, opportunity for record date capture and governance improvements

2/3 on May 18, enter BSE Pharma basket pre-results for sector momentum without financial downside yet

Sun Pharma May 24 watch for insider buys post-results, SPARC 48hrs after May 18 signals conviction

BSE 524715/NSE SUNPHARMA dividend + results combo undervalued vs historical capital returns

Ratify 2024 EGM resolutions + FY26 reports approval, potential re-rating for Gujarat-based pharma

Neutral sentiment + no margin/ROE declines disclosed, pharma outperform vs broader market into May catalysts

SPARC (6/10) vs Natural (3/10) May 18 pairing, favor Sun affiliate for higher alpha post-results

3/3 BSE Pharma filings cluster board meetings May 18-22 for FY26 results, aggregate catalyst density high vs typical quarterly spread [IMPLICATION: Preemptive positioning]

Sun Pharma (8/10 materiality) flags dividend recommendation, 1/3 filings with explicit shareholder returns vs reinvestment silence elsewhere [IMPLICATION: Yield hunters favor leaders]

All 3 closed from April 1 (Sun to May 24, others post-results), no insider trades/pledges enforces SEBI compliance [IMPLICATION: Reduces leak risk, builds anticipation]

Large-cap Sun Pharma 8/10 vs mid/small SPARC 6/10/Natural 3/10, highlights tiered impact in pharma [IMPLICATION: Selective allocation to high-materiality names]

2/3 (Sun Pharma CIN L24230GJ1993PLC019050, Natural L24299GJ1992PLC018210) Gujarat-based, regional operational synergies [IMPLICATION: Local policy tailwinds]

All neutral with no YoY trends/guidance, masks potential margin/growth beats [IMPLICATION: Asymmetric upside post-disclosure]

FY26 results + dividend rec on May 22, 2026; monitor declaration and AGM tie-in [May 22]

Audited Q4/FY26 results on May 18, 2026; watch trading window reopen 48hrs after for insider activity [May 18]

FY26 reports, AGM/book closure dates on May 18, 2026; track scrutinizer and e-voting details [May 18]

Reopens May 24, 2026; monitor CEO/KMP buys post-results for conviction [May 24]

Closure ends 48hrs after May 18 results submission; watch for pledges/holdings changes [Post-May 18]

Fixed dates post-May 18; monitor record date for participation alpha [TBD post-May 18]

Post-board filings for YoY revenue/margins vs sector; flag guidance changes [May 18-24]

All windows closed since April 1; post-reopen patterns across BSE Pharma for conviction trends [May 24+]